Author/Editor     Bekfani, Tarek; Pellicori, Pierpaolo; Morris, Daniel A.; Ebner, Nicole; Valentova, Miroslava; Steinbeck, Lisa; Wachter, Rolf; Elsner, Sebastian; Sliziuk, Veronika; Schefold, Joerg C.; Lainščak, Mitja
Title     Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life
Type     članek
Vol. and No.     Letnik 222, št. 1 November 2016
Publication year     2016
Volume     str. 41-46
ISSN     2352-9067 - International journal of cardiology
Language     eng
Abstract     Background. To describe the prevalence of sarcopenia in ambulatory patients with heart failure with preserved ejection fraction (HFpEF) and its relation to reduced exercise capacity, muscle strength, and quality of life (QoL). Methods and results. A total of 117 symptomatic outpatients with HFpEF were prospectively enrolled in Germany, England, and Slovenia as part of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Appendicular skeletal muscle (ASM) mass (the sum of muscle mass in both arms and legs) was assessed by DEXA. Echocardiography, 6-minute walk testing (6-MWT), muscle strength assessment, spiroergometry and QoL evaluation using EQ-5D Questionnaire were performed. Sarcopenia was defined as ASM 2 standard deviations below the mean of a healthy reference group aged 18-40 years. Patients were divided into 3 groups according to the E/e' value: < 8, 9-14, and > 15. Sarcopenia was detected in 19.7% of all patients. These patients performed worse during 6-MWT (404 +/- 116 vs. 307 +/- 145 m, p = 0.003) and showed lower absolute peak oxygen consumption (1579 +/- 474 vs. 1211 +/- 442 mL/min, p < 0.05). Both ASM and muscle strength were lowest in patients with E/e' > 15 (p < 0.05). Higher values of muscle strength/ASM were associated with a better QoL (r = 0.5, p < 0.0005). Logistic regression showed ASM to be independently associated with reduced distance walked during the 6-MWT adjusted for NYHA, height, left atrium diameter, ferritin and forced expiratory volume in 1 s (FEV1) (odds ratio 1.2, p = 0.02). Conclusion. Sarcopenia affects a clinically relevant proportion of patients with HFpEF. Low ASM is strongly linked to reduced muscle strength, exercise capacity and QoL in these patients.
Descriptors     Heart failure
Sarcopenia
Exercise tolerance
Quality of life
Popuščanje srca
Sarkopenija
Telesna zmogljivost
Kakovost življenja